Investment in the treatment of rare and orphan diseases continues to significantly grow as the pharmaceutical and biotech industry diverges their attention to novel drug development. Despite the momentous shift in attention to smaller patient populations affected by rare disease, Contract Research Organizations (CROs) now face new challenges to develop relevant animal models that properly ‘recapitulate features of human disorder’.
This industry shift in focus has lead to new strategizing plans in the development of partnerships with CROs, promoting innovative partnerships rather than transactional interactions. In the past 2 years, the FDA has approved 40% of rare and orphan drugs, which are estimated to take up 20% of prescriptions by 2024. The development of relevant animal models and rate of approval are said to advance as this new approach is implemented.
it is iNtRON.